Sound Shore Management Has Trimmed By $18.28 Million Its Keysight Technologies (KEYS) Holding; Last Week Infinity Pharmaceuticals, Inc. (INFI) Coverage

April 24, 2018 - By Ellis Scott

Keysight Technologies, Inc. (NYSE:KEYS) Logo

Sound Shore Management Inc decreased Keysight Technologies Inc. (KEYS) stake by 10.26% reported in 2017Q4 SEC filing. Sound Shore Management Inc sold 445,891 shares as Keysight Technologies Inc. (KEYS)’s stock rose 22.03%. The Sound Shore Management Inc holds 3.90M shares with $162.32M value, down from 4.35 million last quarter. Keysight Technologies Inc. now has $10.17 billion valuation. The stock increased 1.25% or $0.67 during the last trading session, reaching $54.23. About 910,040 shares traded or 2.67% up from the average. Keysight Technologies, Inc. (NYSE:KEYS) has risen 40.58% since April 24, 2017 and is uptrending. It has outperformed by 29.03% the S&P500.

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Wedbush upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Tuesday, June 14. Wedbush has “Neutral” rating and $1.50 target. On Friday, August 7 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Hold” rating given on Monday, August 10 by Zacks. JMP Securities maintained it with “Market Outperform” rating and $17 target in Wednesday, March 9 report. Wells Fargo upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Thursday, October 12 to “Outperform” rating. The firm has “Overweight” rating given on Monday, September 21 by Morgan Stanley. As per Tuesday, March 22, the company rating was downgraded by Wedbush. The rating was downgraded by on Tuesday, June 14 to “Neutral”. The firm has “Hold” rating by Jefferies given on Wednesday, June 15. FBR Capital initiated the stock with “Outperform” rating in Wednesday, March 2 report. See Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) latest ratings:

The stock decreased 1.79% or $0.04 during the last trading session, reaching $2.2. About 299,323 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 38.35% since April 24, 2017 and is downtrending. It has underperformed by 49.90% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $114.32 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Investors sentiment increased to 0.62 in Q4 2017. Its up 0.15, from 0.47 in 2017Q3. It improved, as 11 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 12 funds opened positions while 9 raised stakes. 24.33 million shares or 10.88% less from 27.30 million shares in 2017Q3 were reported. Royal State Bank Of Canada accumulated 227 shares. National Bank & Trust Of Mellon invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Geode Mgmt Ltd Liability Company accumulated 325,567 shares. Morgan Stanley owns 12,684 shares. Tortoise Investment Management Ltd invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Dimensional Fund Advisors Lp stated it has 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). American Financial Grp Inc stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). 1.89 million are owned by Vanguard Grp Incorporated. Macquarie Group Ltd reported 4,700 shares. Guggenheim Capital holds 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) or 13,406 shares. Tower Limited Liability Company (Trc) holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 1,664 shares. Savant Capital Limited Liability holds 16,250 shares. Qs Investors Limited has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Bogle Investment Mngmt L P De owns 219,652 shares. Federated Pa accumulated 2,191 shares.

Since March 5, 2018, it had 1 insider buy, and 1 insider sale for $2.96 million activity. The insider Perkins Adelene Q sold 5,000 shares worth $13,890. 1.51 million shares valued at $2.97M were bought by BVF PARTNERS L P/IL on Monday, April 9.

Among 10 analysts covering Keysight Technologies Inc (NYSE:KEYS), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Keysight Technologies Inc had 41 analyst reports since August 17, 2015 according to SRatingsIntel. Deutsche Bank maintained it with “Buy” rating and $4600 target in Wednesday, June 7 report. The firm has “Buy” rating by Jefferies given on Tuesday, August 22. The firm earned “Outperform” rating on Friday, March 2 by Credit Suisse. Stifel Nicolaus maintained it with “Hold” rating and $40 target in Wednesday, June 7 report. The firm earned “Outperform” rating on Friday, June 16 by Robert W. Baird. The rating was initiated by Deutsche Bank on Tuesday, December 1 with “Hold”. The company was upgraded on Monday, September 19 by Deutsche Bank. The stock of Keysight Technologies, Inc. (NYSE:KEYS) has “Neutral” rating given on Friday, January 8 by Robert W. Baird. Deutsche Bank maintained Keysight Technologies, Inc. (NYSE:KEYS) on Monday, March 5 with “Buy” rating. The stock of Keysight Technologies, Inc. (NYSE:KEYS) has “Buy” rating given on Thursday, December 7 by Jefferies.

Analysts await Keysight Technologies, Inc. (NYSE:KEYS) to report earnings on June, 5. They expect $0.76 earnings per share, up 28.81% or $0.17 from last year’s $0.59 per share. KEYS’s profit will be $142.53 million for 17.84 P/E if the $0.76 EPS becomes a reality. After $0.44 actual earnings per share reported by Keysight Technologies, Inc. for the previous quarter, Wall Street now forecasts 72.73% EPS growth.

Investors sentiment increased to 1.06 in 2017 Q4. Its up 0.13, from 0.93 in 2017Q3. It improved, as 26 investors sold KEYS shares while 97 reduced holdings. 47 funds opened positions while 83 raised stakes. 162.12 million shares or 0.80% more from 160.84 million shares in 2017Q3 were reported. Louisiana State Employees Retirement Sys holds 0.09% or 46,900 shares in its portfolio. Central Secs has 295,000 shares for 1.97% of their portfolio. Hsbc Holdg Public Limited holds 0.01% in Keysight Technologies, Inc. (NYSE:KEYS) or 124,173 shares. Ameritas Prtn Incorporated holds 0.1% of its portfolio in Keysight Technologies, Inc. (NYSE:KEYS) for 55,272 shares. Envestnet Asset Mngmt owns 37,943 shares. State Of Alaska Department Of Revenue accumulated 11,000 shares. World Asset Management Inc holds 11,707 shares. Shell Asset Mgmt Co holds 27,493 shares or 0.02% of its portfolio. Moreover, Macquarie Grp has 0.01% invested in Keysight Technologies, Inc. (NYSE:KEYS). Texas Yale Cap has invested 0.13% in Keysight Technologies, Inc. (NYSE:KEYS). 103,725 were reported by Clifford Swan Counsel Lc. Df Dent accumulated 8,618 shares. Massachusetts Service Communications Ma stated it has 1.30M shares or 0.02% of all its holdings. Nelson Roberts Inv Advsr Llc holds 183 shares or 0% of its portfolio. The Switzerland-based Jabre Capital Ptnrs Sa has invested 0.05% in Keysight Technologies, Inc. (NYSE:KEYS).

Sound Shore Management Inc increased Antero Resources Corporation (NYSE:AR) stake by 866,217 shares to 10.80 million valued at $205.18 million in 2017Q4. It also upped Oracle Corporation (NYSE:ORCL) stake by 59,276 shares and now owns 3.88M shares. Pentair Plc (NYSE:PNR) was raised too.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: